Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report

  title={Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report},
  author={Claus F. Vogelmeier and Gerard J. Criner and Fernando J. Martinez and Antonio Anzueto and Peter J. Barnes and Jean Bourbeau and Bartolom{\'e} R. Celli and Rongchang Chen and Marc Decramer and Leonardo M. Fabbri and Peter A. Frith and David M. G. Halpin and Maria Victorina Lopez Varela and Masaharu Nishimura and Nicolas Roche and Roberto Rodr{\'i}guez-Rois{\'i}n and Don D. Sin and Dave Singh and Robert A Stockley and J{\o}rgen Vestbo and Jadwiga A Wedzicha and Alvar Agust{\'i}},
  pages={575 - 601}
This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and… 
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
Blood eosinophils are recommended as a biomarker to support clinical decisions regarding the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients, based on recent evidence from clinical trials.
COPD Guidelines: A Review of the 2018 GOLD Report
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?
Phenotyping provides potential for a more personalized approach than the former model of care because it allows clustering patients defined by clinical characteristics and sharing common clinical outcomes, but is still too much of a simplistic method that, in any case, must be validated in future clinical studies.
Defining severe obstructive lung disease in the biologic era: an endotype-based approach
The definition of severe obstructive lung disease must be updated so that it includes all patients who could benefit from novel treatments and for whom associated costs are justified, allowing targeted biologic therapies to benefit a greater proportion and range of patients.
Outcome of Regular Inhaled Treatment in GOLD A Chronic Obstructive Pulmonary Disease Patients
Regular inhaled treatment in group A patients with COPD was associated with a symptomatic benefit but not with a reduction of exacerbation rates.
Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve
Pulmonologist adherence to the GOLD guidelines is not optimal and needs to be improved, and among the factors that influence the inappropriateness of COPD treatments, cardiovascular comorbidities and low-risk Groups A and B are important.
Implementation of the chronic obstructive pulmonary disease Assessment Test in clinical practice
  • M. Abrams
  • Medicine
    Journal of the American Association of Nurse Practitioners
  • 2020
Implementation and utilization of COPD assessment tools, like the CAT, are practical and sustainable in a specialty practice setting and moreover, the CAT helps with COPD symptom management.
Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD)
This review will explore the most promising blood and sputum protein biomarkers in COPD that have been consistently reported in the literature and fill in potential gaps between biomarker discovery and patient care.
Stable Chronic Obstructive Pulmonary Disease (COPD) Management Under a Tiered Medical System in China
Differences exist in the diagnosis, treatment and management of COPD among different tiers of hospitals in China and teaching hospitals can manage COPD patients relatively well.


Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
The main goals of the updated document are to improve the quality of care provided to patients with COPD and to develop the project using a disease-oriented approach.
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
Integrated disease management interventions for patients with chronic obstructive pulmonary disease.
Compared with controls, IDM showed a statistically and clinically significant improvement in disease-specific QoL on all domains of the Chronic Respiratory Questionnaire after 12 months and quality of evidence was scored as high quality, and on the CRQ as moderate quality evidence.
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.
The DOSE Index is a simple, valid tool for assessing the severity of COPD, related to a range of clinically important outcomes such as health care consumption and predicts future events.
COPD exacerbations: defining their cause and prevention
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
Patients and clinicians should balance the potential benefits of inhaled steroids in COPD (reduced rate of exacerbations, reduced rate of decline in quality of life), against the known increase in local side effects (oropharyngeal candidiasis and hoarseness).
Mortality in COPD: role of comorbidities
The current paper reviews the role of comorbidities in chronic obstructive pulmonary disease mortality, the putative underlying pathogenic link between chronic obstructives pulmonary disease and comorbrid conditions (i.e. inflammation), and the tools used to predict Chronic obstructivemonary disease mortality.
Complex chronic comorbidities of COPD
The current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise patients with COPD.